Adma Biologics (ADMA) Other Non-Current Assets (2011 - 2025)

Adma Biologics' Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $8.6 million for Q4 2025.

• Quarterly Other Non-Current Assets rose 52.02% year-over-year to $8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.6 million (up 52.02% YoY) and the FY2025 annual result came in at $8.6 million, up 52.02% from the prior year.
• Other Non-Current Assets was $8.6 million for Q4 2025 at Adma Biologics, down from $8.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $9.1 million in Q2 2025 and bottomed at $2.2 million in Q1 2021.
• A 5-year average of $5.4 million and a median of $5.0 million in 2022 frame the typical range for Other Non-Current Assets.
• Peak annual rise in Other Non-Current Assets reached 93.04% in 2021, while the deepest fall reached 35.85% in 2021.
• Adma Biologics' Other Non-Current Assets stood at $4.1 million in 2021, then rose by 17.27% to $4.8 million in 2022, then retreated by 2.1% to $4.7 million in 2023, then increased by 21.13% to $5.7 million in 2024, then jumped by 52.02% to $8.6 million in 2025.
• Business Quant data shows ADMA's Other Non-Current Assets at $8.6 million in Q4 2025, $8.8 million in Q3 2025, and $9.1 million in Q2 2025.